Gentian Diagnostics invites to NT-proBNP educational webinar

About this update from Gentian Diagnostics Asa

Moss, 28 January 2026Gentian Diagnostics ASA will host an educational webinar focused on NT-proBNP,awidely used biomarker in the diagnosis and management of heart failure.The live webinar will take place on 25 February 2026 at 15:00 CET and willfeature presentations by Peder L. Myhre, Professor of Cardiology at theUniversity of Oslo, and Robert H. Christenson, Professor of Pathology at theUniversity of Maryland School of Medicine.The webinar will address current clinical use of NT-proBNP as well asbiologicaland analytical challenges, including the impact of NT-proBNP glycosylation onassay performance and clinical interpretation.The webinar forms part of Gentian's ongoing scientific and educationaloutreachrelated to its NT-proBNP development program. A recording will be madeavailablefollowing the live event.The webinar is hosted by Labroots and can be accessed via the following link:https://www.labroots.com/ms/webinar/glycosylation-nt-probnp-clinicians-laboratoriesFor further information, please contact: Njaal Kind, [email protected] +47 919 06 525About Gentian Diagnostics Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, invitro diagnostic reagents. Our mission is to innovate diagnostic efficiencyforbetter treatment decisions. Gentian's expertise and focus lie withinimmunoassays, specifically for infections, inflammation, kidney disease andheart failure. By converting existing and clinically relevant biomarkers tothemost efficient, high-throughput analysers, the company contributes to savingcosts and protecting life. Gentian Diagnostics is headquartered in Moss,Norway,serving the global human and veterinary diagnostics markets through sales andrepresentative offices in Sweden, USA, and China. For more information, pleasevisit www.gentian.com.https://newsweb.oslobors.no/message/664354

View stock analysis, news, and events for Gentian Diagnostics Asa